is covid vaccine net benefit for 0 to 16 year olds

For children 0-16, the COVID vaccine’s net benefit is not clearly proven; the evidence for preventing serious outcomes in this age group is thin, while a known harm—myocarditis—is documented, especially in boys.

The question is not about adults or the elderly, who make up the overwhelming majority of every study in the retrieved evidence. Studies showing reduced mortality or hospitalization in older adults [1, 2, 3, 4] do not answer the question for children. The only retrieved study specific to children is a 2025 CDC-funded test-negative design in the VISION network [6]. It found that the 2024-2025 vaccine reduced emergency department and urgent care visits by about 76% in children 9 months to 4 years and about 56% in those 5-17 years, within 7-179 days [6]. That is a moderate effect against a mild outcome—ED visits, not death or ICU admission—and it wanes over longer windows [6]. No retrieved study measures the vaccine’s effect on all-cause mortality or serious long-term outcomes in otherwise healthy children.

The most concrete harm in this age group is myocarditis. A meta-analysis of adolescents 12-17 found a rate of about 15.7 per 100,000 in boys after the second dose of Pfizer’s mRNA vaccine, compared to about 6.1 per 100,000 in girls [5]. That is about 1 in 6,400 boys. The same study reports that SARS-CoV-2 infection itself carries a higher myocarditis risk—about 2 to 35 times higher depending on dose and sex [5]. But the question is about net benefit: do you trade a rare but real vaccine injury for a rarer infection injury? In young children, the background risk of serious COVID-19 is very low, so the trade is not obviously favorable.

The evidence does not include a single long-term safety trial in children comparing vaccinated to unvaccinated peers. The 2024 ACIP meeting notes mention safety signals for Guillain-Barré and ischemic stroke in older adults after mRNA vaccines [7], but for children, the safety data is short-term only. The burden of proof has not been met for this population.

Confidence is low that the vaccine provides a net clinical benefit for all children 0-16. The limited evidence shows a moderate, short-term reduction in mild outcomes, while the known hazard of vaccine myocarditis is concentrated in the same adolescent boys who are at lowest risk from the disease itself. For healthy children under 5, the benefit is even less clear.